SEC Tracker
Get the app

BridgeBio Oncology Therapeutics BBOT

BridgeBio Oncology Therapeutics appoints Eli Wallace as PubCo’s Chief Executive Officer

Form
8-K
Filed
Importance
Routine
  • Signs a material agreement (1.01)
  • Completes an acquisition or sale of assets (2.01)
  • Sells unregistered shares (3.02)
  • Changes shareholder rights (3.03)
  • Changes its auditor (4.01)
  • Reports a change in control (5.01)
  • Reports an executive or board change (5.02)
  • Amends its charter or bylaws (5.03)
  • Changes its ethics code (5.05)
  • Changes its shell company status (5.06)
  • Makes a Regulation FD disclosure (7.01)
  • Discloses other events (8.01)

Not explained yet; the original is on EDGAR.

View on EDGAR

Open in the app

Get an email when BridgeBio Oncology Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. aTYR PHARMA ATYR public float $464M, Jun 30, 2025
  2. Arvinas ARVN public float $469M, Jun 30, 2025
  3. Arbutus Biopharma ABUS public float $472M, Jun 30, 2025
  4. Zevra Therapeutics ZVRA public float $455M, Jun 30, 2025
  5. Theravance Biopharma TBPH public float $449M, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.